Cargando…

Glu-Urea-Lys Scaffold Functionalized Superparamagnetic Iron Oxide Nanoparticles Targeting PSMA for In Vivo Molecular MRI of Prostate Cancer

The prostate specific membrane antigen (PSMA), extensively overexpressed on prostate cancer (PCa) cell surface, has been validated as a diagnostic biomarker for PCa. However, insufficient attention has been paid to the development of PSMA-specific probes loaded with small chemical molecules for the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Wei, Huang, Jiandong, Xiao, Qingwei, Hu, Shunmin, Li, Shijia, Zheng, Jie, Du, Zhiyun, Peng, Jiangling, Chen, Huixiong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9608448/ https://www.ncbi.nlm.nih.gov/pubmed/36297485 http://dx.doi.org/10.3390/pharmaceutics14102051

Ejemplares similares

Synthesis of an Al(18)F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand in an automated synthesis platform
por: Giglio, Javier, et al.
Publicado: (2018)

Lys-urea-Aad, Lys-urea-Cmc and Lys-urea-Cms as potential pharmacophores for the design of PSMA-targeted radioligands to reduce off-target uptake in kidneys and salivary glands
por: Kuo, Hsiou-Ting, et al.
Publicado: (2023)

In Vivo Molecular MRI Imaging of Prostate Cancer by Targeting PSMA with Polypeptide-Labeled Superparamagnetic Iron Oxide Nanoparticles
por: Zhu, Yunkai, et al.
Publicado: (2015)

What a difference a methylene makes: replacing Glu with Asp or Aad in the Lys-urea-Glu pharmacophore of PSMA-targeting radioligands to reduce kidney and salivary gland uptake
por: Kuo, Hsiou-Ting, et al.
Publicado: (2022)

PSMA PET/CT with Glu-urea-Lys-(Ahx)-[(68)Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer
por: Giesel, Frederik L., et al.
Publicado: (2015)

(177)Lu-DOTA-HYNIC-Lys(Nal)-Urea-Glu: Biokinetics, Dosimetry, and Evaluation in Patients with Advanced Prostate Cancer
por: Santos-Cuevas, Clara, et al.
Publicado: (2018)

Synthesis and preclinical evaluation of novel (18)F-labeled Glu-urea-Glu-based PSMA inhibitors for prostate cancer imaging: a comparison with (18)F-DCFPyl and (18)F-PSMA-1007
por: Robu, Stephanie, et al.
Publicado: (2018)

A Glu-urea-Lys Ligand-conjugated Lipid Nanoparticle/siRNA System Inhibits Androgen Receptor Expression In Vivo
por: Lee, Justin B, et al.
Publicado: (2016)

Synthesis and Evaluation of (99m)Tc-Labeled PSMA-Targeted Tracers Based on the Lys-Urea-Aad Pharmacophore for Detecting Prostate Cancer with Single Photon Emission Computed Tomography
por: Lu, Kelly, et al.
Publicado: (2023)

Origin and Spread of the ALDH2 Glu504Lys Allele
por: Zhang, Xiaokai, et al.
Publicado: (2021)

MMP-8 C-799 T, Lys460Thr, and Lys87Glu variants are not related to risk of cancer
por: Zhang, Li-Feng, et al.
Publicado: (2019)

Incorporation of Superparamagnetic Iron Oxide Nanoparticles into Collagen Formulation for 3D Electrospun Scaffolds
por: Estévez, Manuel, et al.
Publicado: (2022)

Prostate MRI and PSMA-PET in the Primary Diagnosis of Prostate Cancer
por: Cereser, Lorenzo, et al.
Publicado: (2023)

Optimized (68)Ga-Labeled Urea-Based PSMA-Targeted PET Tracers for Prostate Cancer
por: Wu, Yitian, et al.
Publicado: (2022)

Self-Assembled Superparamagnetic Iron Oxide Nanoclusters for Universal Cell Labeling and MRI
por: Chen, Shuzhen, et al.
Publicado: (2016)

Clinical perspectives of PSMA PET/MRI for prostate cancer
por: Barbosa, Felipe de Galiza, et al.
Publicado: (2018)

Design of Internalizing PSMA-specific Glu-ureido-based Radiotherapeuticals
por: Wüstemann, Till, et al.
Publicado: (2016)

Plasma phenotypes of protein S Lys196Glu and protein C Lys193del variants prevalent among young Japanese women
por: Noguchi, Kenta, et al.
Publicado: (2019)

Size-isolation of superparamagnetic iron oxide nanoparticles improves MRI, MPI and hyperthermia performance
por: Dadfar, Seyed Mohammadali, et al.
Publicado: (2020)

GCP III is not the “off-target” for urea-based PSMA ligands
por: Lee, Zhenghong, et al.
Publicado: (2023)

Role of aldehyde dehydrogenase 2 Glu504lys polymorphism in acute coronary syndrome
por: Xu, Feng, et al.
Publicado: (2011)

Association between ALDH2 Glu487Lys polymorphism and the risk of esophageal cancer
por: Liu, Kang, et al.
Publicado: (2017)

Targeted delivery of cytotoxic proteins to prostate cancer via conjugation to small molecule urea-based PSMA inhibitors
por: Rogers, O. C., et al.
Publicado: (2021)

Association of a Missense ALDH2 Single Nucleotide Polymorphism (Glu504Lys) With Benign Prostate Hyperplasia in a Korean Population
por: Seok, Hosik, et al.
Publicado: (2013)

In vivo MRI visualization of mesh shrinkage using surgical implants loaded with superparamagnetic iron oxides
por: Kuehnert, Nicolas, et al.
Publicado: (2011)

Clinically Translatable Cell Tracking and Quantification by MRI in Cartilage Repair Using Superparamagnetic Iron Oxides
por: van Buul, Gerben M., et al.
Publicado: (2011)

MRI detection of endothelial cell inflammation using targeted superparamagnetic particles of iron oxide (SPIO)
por: Chan, Joyce M. S., et al.
Publicado: (2017)

Neural Induction Potential and MRI of ADSCs Labeled Cationic Superparamagnetic Iron Oxide Nanoparticle In Vitro
por: Ma, Weiqiong, et al.
Publicado: (2018)

New MRI contrast agents based on silicon nanotubes loaded with superparamagnetic iron oxide nanoparticles
por: Gonzalez-Rodriguez, Roberto, et al.
Publicado: (2018)

Polymer-coated superparamagnetic iron oxide nanoparticles as T(2) contrast agent for MRI and their uptake in liver
por: Ali, Lamiaa MA, et al.
Publicado: (2017)

Superparamagnetic iron oxide-enhanced MRI-guided stereotactic ablative radiation therapy for liver metastasis
por: Hama, Yukihiro, et al.
Publicado: (2021)

A Simple & Convenient Solid Phase Synthesis of Bacterial Origin Octapeptide Sequence, Glu-Asp-Gly-Asn-Lys-Pro-Gly-Lys-OH
por: Khan, Riaz A.
Publicado: (2010)

Washing effect on superparamagnetic iron oxide nanoparticles
por: Mireles, Laura-Karina, et al.
Publicado: (2016)

Polydopamine Modified Superparamagnetic Iron Oxide Nanoparticles as Multifunctional Nanocarrier for Targeted Prostate Cancer Treatment
por: Singh, Nimisha, et al.
Publicado: (2019)

Gross tumor volume delineation in primary prostate cancer on (18)F-PSMA-1007 PET/MRI and (68)Ga-PSMA-11 PET/MRI
por: Zhang, Yan-Nan, et al.
Publicado: (2022)

Physicochemical characterization of ultrasmall superparamagnetic iron oxide particles (USPIO) for biomedical application as MRI contrast agents
por: Di Marco, Mariagrazia, et al.
Publicado: (2007)

Superparamagnetic Iron Oxide Nanoparticles as MRI contrast agents for Non-invasive Stem Cell Labeling and Tracking
por: Li, Li, et al.
Publicado: (2013)

Value of Functionalized Superparamagnetic Iron Oxide Nanoparticles in the Diagnosis and Treatment of Acute Temporal Lobe Epilepsy on MRI
por: Fu, Tingting, et al.
Publicado: (2016)

Synthesis of a cell penetrating peptide modified superparamagnetic iron oxide and MRI detection of bladder cancer
por: Ding, Chen, et al.
Publicado: (2016)

Validation of MRI quantitative susceptibility mapping of superparamagnetic iron oxide nanoparticles for hyperthermia applications in live subjects
por: Deh, Kofi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_89fj0p3nq46g3hbp1r64a7nmla